Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer
Authors:
- 1 June 1992
- journal article
- clinical trial
- Published by Springer Nature in Biotherapy
- Vol. 4 (2) , 117-128
Abstract
The present study was designed to assess the effects of the protein-bound polysaccharide PSK on the immunological status of patients with gastrointestinal cancer. Twenty-nine gastric and 18 colorectal cancer patients were randomly assigned to either the control or PSK group. Patients in the PSK group were given 3.0 g of PSK orally before surgery, either daily or every other day. Patients in the control group received no PSK. The data of peripheral blood lymphocytes (PBL) were compared before and after administration of PSK, and those of the regional node lymphocytes (RNL) were compared between the control and the PSK group. The results indicate that the effects of PSK were significantly influenced by the duration of administration, but not by the frequency of administration. In the patients belonging to the short term PSK group (administration <14 days), the response of the PBL to PSK and Con A become significantly stronger compared to before the administration of PSK, whereas the cytotoxicity against K562 and KATO-3, and the proportion of CD16+ cells increased significantly in those patients belonging to the long term PSK group (≧14 days). In addition, the proportion of CD9 + 11b + suppressor T cells decreased in the RNL of the short term PSK group, whereas the proportion of CD4 + Leu8 - helper T cells in the RNL increased in the long term PSK group. These results suggest that the oral administration of PSK leads to the suppression of suppressor cells in the RNL. Thus, increased numbers of cytotoxic effector cells appear to be activated in the PBL while helper T cells predominate in the RNL.Keywords
This publication has 17 references indexed in Scilit:
- In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancerCancer Immunology, Immunotherapy, 1991
- Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancerCancer Immunology, Immunotherapy, 1990
- Blocking of lymphocyte surface binding sites for the soluble suppressor factor by protein-bound polysaccharide, PSKInternational Journal of Immunopharmacology, 1989
- Morphological and biochemical alterations of macrophages produced by a glycan, PSKImmunopharmacology, 1988
- Antitumor Effector Mechanism at a Distant Site in the Double Grafted Tumor System of PSK, a Protein-bound Polysaccharide PreparationJapanese Journal of Cancer Research, 1988
- Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin®)International Journal of Immunopharmacology, 1988
- Effects of PSK on Interleukin-2 Production by Peripheral Lymphocytes of Patients with Advanced Ovarian Carcinoma during ChemotherapyJapanese Journal of Cancer Research, 1988
- Effect of immunostimulants and antitumor agents on Tumor Necrosis Factor (TNF) productionInternational Journal of Immunopharmacology, 1987
- Effect of a protein bound polysaccharide (PS-K) on tumor development and infections in splenectomized rats and miceInternational Journal of Immunopharmacology, 1986
- The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigensInternational Journal of Immunopharmacology, 1983